Tesaro, Inc. (NASDAQ:TSRO) kept in active run as it traded at $118.68 by are plunging -1.36%. An oncology-focused biopharmaceutical company provided a summary of ZEJULA and TSR-042, an anti-PD-1 antibody, data presented at the 2017 European Society of Medical Oncology (ESMO) Annual Meeting in Madrid. “ZEJULA is the market-leading PARP inhibitor, with unsurpassed efficacy in a broad patient population and convenient, once-daily dosing,” said Mary Lynne Hedley, Ph.D., President and COO of TESARO.
“Watchful waiting’ is no longer an acceptable option for women living with ovarian cancer. We believe combination approaches, including niraparib and anti-PD-1 antibodies, will become increasingly important and we are executing on our registration strategy for TSR-042, our anti-PD-1 antibody, in MSI-high cancers.” ZEJULA (niraparib) presentations: Treatment with niraparib did not impact patient quality of life in the NOVA trial Quality of life measures are important to understanding the benefit of niraparib in the maintenance treatment setting. Dr. Amit M. Oza, M.D., Senior Staff Physician, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, presented quality of life (QoL) data from the Phase 3 ENGOT-OV16/NOVA trial.
Patient-declared outcomes (PROs) were evaluated along with individual patient-declared symptoms using the Functional Assessment of Cancer Therapy-Ovarian Symptoms Index (FOSI) and European Quality of Life Scale 5-Dimensions (EQ-5D-5L). The most common PRO symptoms at baseline were fatigue and pain, and 20% of patients experienced nausea at baseline. No important difference in mean patient-declared outcomes (PRO) scores was observed between patients treated with niraparib versus placebo, regardless of germline BRCAmutation status. Hematologic adverse events (thrombocytopenia, neutropenia, anemia) reduced over time with dose modification and did not impact QoL. These results also suggest that patients with ovarian cancer often experience residual symptoms of their disease following the conclusion of chemotherapy.
Horizon Pharma Public Limited Company (NASDAQ:HZNP) shares shows upbeat performance surged after opening to traded at $14.05 with volume of 3.32 Million shares.
Horizon Pharmaplc (NASDAQ:HZNP) named Irina Konstantinovsky executive vice president, chief human resources officer, reporting directly to Timothy P. Walbert, chairman, president and chief executive officer, effective immediately. “Irina is an accomplished human resources professional with an excellent track record of attracting, developing and retaining talent as well as building an inclusive and engaging culture,” said Walbert. “Her extensive experience will be critical as the company continues to grow and evolve.” Prior to Horizon, Konstantinovsky was vice president of worldwide talent at Baxter International Inc. where she led a team of talent professionals worldwide and oversaw organizational effectiveness, leadership development, inclusion and diversity and talent acquisition. She and her team were responsible for talent management strategies, programs and systems for more than 50,000 employees worldwide. “Horizon Pharma has a strong, patient-centered culture with passionate, committed employees at its core,” said Konstantinovsky. “I’m looking forward to helping build a world-class human resources function that continues to foster and develop these strengths.”
HZNP is ahead its 52-week low with 48.68%and going down from its 52-week high price with -36.08%. The company’s shares performance for the last one month was 21.75% and 3.16% in the previous week.
As the revenues measures, firm has operation margin of -43.00% in the following twelve months with net profit margin of negative -42.40%. The Company showed a negative -42.40% in the net profit margin. Company’s annual sales growth for the past five year was 169.30%.